Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Interest Income

Income earned on cash, deposits, and investments held by the company.

Biohaven Ltd.NYSE: BHVN

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income remains negative

Q2 FY2026 interest income was $0, compared with $4.15M a year earlier. Trailing-twelve-month interest income was $6.23M.

Context

  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.56M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$14.59M-31.6% YoY
LTMJun 2026
$6.23M-69.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-31.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
14.59M USD
Year-over-year change
-31.6%

Interest Income vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -69.3% is the lowest of 10, against a peer median of -6.9%.
BHVN Competitors
Interest Income for BHVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$25.8M USD-41.1%+50.6%39.0%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$25.4M USD-19.9%+114.3%22679.5%
VERAVera Therapeutics, Inc.LTM Jun 2026$22.96M USD-6.9%+140.9%—
IMNMImmunome, Inc.LTM Sep 2026$18.04M USD+57.2%+1228.3%—
IMCRImmunocore Holdings plcLTM Mar 2026$14.94M USD-30.5%+63.7%3.9%
SIONSionna Therapeutics, Inc.LTM Mar 2026$13.12M USD+30.7%+127.3%—
ABCLAbCellera Biologics Inc.LTM Sep 2026$9.56M USD-69.2%+20.8%14.1%
BHVNBiohaven Ltd.LTM Jun 2026$6.23M USD-69.3%——
PHVSPharvaris N.V.LTM Sep 2026€5.68M EUR+0.7%——
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$4.77M USD+4.3%+22.5%1.5%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$3.02M USD———
Peer median (excluding BHVN) —-6.9%+89.0%14.1%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.14M
Gross Profit0000(4.14M)
Gross Margin—————
Research & Development181.49M437.07M373.28M795.87M635.07M
Selling, General & Admin37.41M130.86M62.77M89.24M106.17M
Operating Expenses218.9M567.93M436.05M885.11M741.24M
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
EBITDA(211.04M)(568.46M)(402.64M)(837.83M)(727.46M)
EBITDA Margin—————
Operating Income(218.9M)(567.93M)(436.05M)(885.11M)(745.38M)
Operating Margin—————
Interest Income0017.73M21.33M14.59M
Interest Expense00000
Other Income / Expenses6.47M(1.91M)26.5M39.42M8M
Income Before Tax(212.43M)(569.84M)(409.55M)(845.69M)(737.38M)
Pre-Tax Margin—————
Income Tax Expense1.37M438K(1.38M)735K1.44M
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Net Margin—————
EPS (Basic)(5.97)(12.75)(5.73)(9.28)(6.86)
EPS (Diluted)(5.97)(12.75)(5.73)(9.28)(6.86)
Weighted Avg Shares35.82M44.74M71.2M91.23M107.62M
Weighted Avg Shares (Diluted)35.82M44.74M71.2M91.23M107.62M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.